Why MacroGenics, Inc.’s (MGNX) Stock Is Up 7.08%
As of Tuesday, October 27, MacroGenics, Inc.’s MGNX share price has surged by 7.08%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 11.56%
As of Monday, October 26, MacroGenics, Inc.’s MGNX share price has dipped by 11.56%, which has investors questioning if this is right time to buy.Michael Rose
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 11.33%
As of Monday, October 26, MacroGenics, Inc.’s MGNX share price has dipped by 11.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 22.07%
As of Friday, October 23, MacroGenics, Inc.’s MGNX share price has dipped by 22.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 35.12%
As of Friday, October 23, MacroGenics, Inc.’s MGNX share price has dipped by 35.12%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $154.2 | $226.9 | 26% |
|
| Shares Out (Mil) | 63.6 | 53.4 | 53% |
|
| Institutional Ownership | 95.1% | 92.9% | 66% |
|
| Float (Mil) | 56.4 | 40.7 | 49% |
|
| Beta | 1.22 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 1,384 | 469 | 76% |
|
| Price Change (52-week) |
43.2% | 46.6% | 83% |
|
| Growth | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.3% | 12.8% | 47% |
|
| Net Income (5yr) | 10.5% | (10.1%) | 56% |
|
| EPS (5yr) | 13.7% | 15.8% | 54 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (31.4%) | (15.7%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | na | 2 | |
| Current EPS | ($0.127) | ($1.558) | ($1.466) | |
| Month Ago EPS | ($0.127) | na | ($1.466) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.313) | $0.035 | ($1.413) | |
| Year/Year Chg | (88.5%) | 31.8% | 34.3% | |
| Financials | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $175 | $37 | 31% |
|
| Net Income (TTM) (Mil) | ($15) | ($44) | 26% |
|
| EPS (TTM) | ($0.230) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($64) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $2 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $131 | $174 | 23% |
|
| Valuation | MGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.61 | 2.17 | 73% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (0.7%) | 65.6% | 4% |
|
| Net Margin | (8.3%) | (71.5%) | 22% |
|
| ROA | (4.9%) | (47.1%) | 30% |
|
| ROE | (32.6%) | (53.0%) | 19% |
|
| Liabilities to Assets | 87.6% | 29.6% | 82% |
|
| F-Score | 4 | 2 | 34% |
|
Passing Stock Screens
As of 10/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
O'Shaughnessy: Tiny Titans Screen
Factors: Value, Size, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
| Performance Since Inception: | 25.5% |
| +/- S&P 500: | +18.1 |
